AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17585971 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg/kg TYR (total 300 mg/kg)
Number of subjects: 19
Study 17585971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 17585971 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold exposure
Number of subjects: 19
Study 15750360 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized homeopathic single remedy
Number of subjects: 0
Study 15750360 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic combination medicine
Number of subjects: 0
Study 15750360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11876695 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole, 30 mg once daily
Number of subjects: 74
Study 11876695 — intervention group
Group type: COMPARATOR
Intervention: Pantoprazole, 40 mg once daily
Number of subjects: 74
Study 10198739 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilated cardiomyopathy (DCM)
Number of subjects: 50
Study 10198739 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic heart disease
Number of subjects: 50
Study 9467524 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion
Number of subjects: 50
Study 9467524 — intervention group
Group type: COMPARATOR
Intervention: Homologous blood transfusion
Number of subjects: 50
Study 9467524 — intervention group
Group type: COMPARATOR
Intervention: Homologous blood transfusion (3-4 units)
Number of subjects: 50
Study 9467524 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion (3-4 units)
Number of subjects: 50
Study 1673233 — intervention group
Group type: EXPERIMENTAL
Intervention: bisoprolol 10 mg o.d.
Number of subjects: 12
Study 1673233 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol 100 mg o.d.
Number of subjects: 12
Study 1673233 — intervention group
Group type: COMPARATOR
Intervention: placebo (during run-in period)
Number of subjects: 12
Study 6811068 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for mild hypertension
Number of subjects: 0
Study 6811068 — intervention group
Group type: EXPERIMENTAL
Intervention: Older subjects
Number of subjects: 0
Study 6811068 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature measurements
Number of subjects: 0
Study 6811068 — intervention group
Group type: EXPERIMENTAL
Intervention: Rainfall
Number of subjects: 0
Study 30513251 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline carriage of N. meningitidis
Number of subjects: 421
Study 30513251 — intervention group
Group type: EXPERIMENTAL
Intervention: Carriage of N. meningitidis at 3 months
Number of subjects: 421
Study 30513251 — intervention group
Group type: COMPARATOR
Intervention: Recovery of N. meningitidis on selective agar
Number of subjects: 421
Study 27189375 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (with alarm)
Number of subjects: 20
Study 27189375 — intervention group
Group type: COMPARATOR
Intervention: Group A (without alarm)
Number of subjects: 20
Study 27402787 — intervention group
Group type: EXPERIMENTAL
Intervention: Pectoralis muscle sling (S)
Number of subjects: 21
Study 27402787 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 21
Study 24861837 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent chemotherapy with TCM
Number of subjects: 76
Study 24861837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 22859063 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR (50, 150, or 300 mg/day)
Number of subjects: 0
Study 22859063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20394494 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleanser A
Number of subjects: 13
Study 20394494 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleanser B (cleanser A plus triclosan, salicylic acid, and azelaic acid)
Number of subjects: 13
Study 18612923 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept alone
Number of subjects: 25
Study 18612923 — intervention group
Group type: COMPARATOR
Intervention: Etanercept in combination with methotrexate (MTX)
Number of subjects: 25
Study 15802771 — intervention group
Group type: EXPERIMENTAL
Intervention: Active vitamin D or its analogs
Number of subjects: 0
Study 11847165 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor treatment
Number of subjects: 161
Study 11847165 — intervention group
Group type: COMPARATOR
Intervention: No ACE inhibitor treatment (Control)
Number of subjects: 161
Study 10774766 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated fat (SF) meal
Number of subjects: 10
Study 10774766 — intervention group
Group type: COMPARATOR
Intervention: Monounsaturated fat (MUFA) meal
Number of subjects: 10
Study 7721921 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous retrograde normothermic
Number of subjects: 20
Study 7721921 — intervention group
Group type: COMPARATOR
Intervention: Intermittent retrograde hypothermic
Number of subjects: 20
Study 1790147 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant gamma-interferon (rGIFN) as a 2-h intravenous infusion daily x 5 every other week at a starting dose of 4.0 x 10(6) IU/m2/day (arm I)
Number of subjects: 50
Study 1790147 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant gamma-interferon (rGIFN) as a 24-h continuous intravenous infusion daily x 5 every month at a starting dose of 2.6 x 10(6) IU/m2/day (arm II)
Number of subjects: 50
Study 7029989 — intervention group
Group type: EXPERIMENTAL
Intervention: salmon calcitonin (100 MRC) plus arginine
Number of subjects: 6
Study 7029989 — intervention group
Group type: COMPARATOR
Intervention: basal conditions
Number of subjects: 6
Study 31079079 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric assessment and management for 6 months
Number of subjects: 350
Study 31079079 — intervention group
Group type: COMPARATOR
Intervention: Usual oncologic care
Number of subjects: 350
Study 27807735 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg/kg body weight oral GHB before going to bed
Number of subjects: 25
Study 27807735 — intervention group
Group type: COMPARATOR
Intervention: Placebo control group
Number of subjects: 25
Study 25504449 — intervention group
Group type: EXPERIMENTAL
Intervention: iTAB (two-way text messaging system)
Number of subjects: 25
Study 25504449 — intervention group
Group type: COMPARATOR
Intervention: CTRL (active comparison)
Number of subjects: 25
Study 23958221 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy based on risk assessment and therapy response in HR+/HER2- patients
Number of subjects: 4936
Study 23958221 — intervention group
Group type: EXPERIMENTAL
Intervention: Short induction treatment for endocrine therapy
Number of subjects: 4936
Study 23958221 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic testing of early therapy response
Number of subjects: 4936
Study 21362312 — intervention group
Group type: EXPERIMENTAL
Intervention: Shensongyangxin (SSYX) capsule
Number of subjects: 859
Study 21362312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 859
Study 21362312 — intervention group
Group type: COMPARATOR
Intervention: Mexiletine tablet
Number of subjects: 859
Study 19340640 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 52
Study 19340640 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 16905632 — intervention group
Group type: EXPERIMENTAL
Intervention: New generation antipsychotics (amisulpride)
Number of subjects: 3725
Study 16905632 — intervention group
Group type: EXPERIMENTAL
Intervention: New generation antipsychotics (olanzapine)
Number of subjects: 3725
Study 16905632 — intervention group
Group type: COMPARATOR
Intervention: Conventional antipsychotics (CAs)
Number of subjects: 3725
Study 15070934 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline treatment for 24 months
Number of subjects: 51
Study 11455866 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg/kg rocuronium
Number of subjects: 48
Study 11455866 — intervention group
Group type: COMPARATOR
Intervention: 0.075 mg/kg vecuronium
Number of subjects: 48
Study 11455866 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 48
Study 9646264 — intervention group
Group type: EXPERIMENTAL
Intervention: High-performance centres (randomized > or = 10 patients)
Number of subjects: 564
Study 9646264 — intervention group
Group type: COMPARATOR
Intervention: Remaining centres (randomized < 10 patients)
Number of subjects: 564
Study 9646264 — intervention group
Group type: EXPERIMENTAL
Intervention: Centres with > or = 2 high-performance centres
Number of subjects: 564
Study 9646264 — intervention group
Group type: COMPARATOR
Intervention: Remaining centres of the same countries
Number of subjects: 564
Study 9646264 — intervention group
Group type: COMPARATOR
Intervention: Centres that randomized 0-1 patient
Number of subjects: 564
Study 7518975 — intervention group
Group type: COMPARATOR
Intervention: CsA
Number of subjects: 121
Study 7518975 — intervention group
Group type: EXPERIMENTAL
Intervention: FK506
Number of subjects: 121
Study 2310658 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% glycerol in saline (500 ml over 4 h on 6 consecutive days)
Number of subjects: 35
Study 2310658 — intervention group
Group type: COMPARATOR
Intervention: Control treatment with saline
Number of subjects: 35
Study 476223 — intervention group
Group type: EXPERIMENTAL
Intervention: d-Amphetamine
Number of subjects: 0
Study 476223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31875775 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel therapeutic game controller and telerehabilitation system
Number of subjects: 7
Study 30790566 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotic fluid index and single deepest pocket measurements
Number of subjects: 1719
Study 28512921 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Bipolar Parenting Intervention (IBPI) plus treatment as usual (TAU)
Number of subjects: 97
Study 28512921 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (WL)
Number of subjects: 97
Study 25557952 — intervention group
Group type: EXPERIMENTAL
Intervention: Simeprevir (150 mg/day) and Sofosbuvir (400 mg/day)
Number of subjects: 82
Study 25557952 — intervention group
Group type: COMPARATOR
Intervention: Peginterferon alfa 2b (1.5 mcg/kg/wk), Ribavirin (1000-1200 mg/day), and Sofosbuvir (400 mg/day)
Number of subjects: 82
Study 23181690 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CKD
Number of subjects: 10271
Study 23181690 — intervention group
Group type: COMPARATOR
Intervention: Patients without CKD
Number of subjects: 10271
Study 23181690 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with stage 1 CKD
Number of subjects: 10271
Study 23181690 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with stage 5 CKD
Number of subjects: 10271
Study 23181690 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled hypertensive patients with CKD
Number of subjects: 10271
Study 21324086 — intervention group
Group type: COMPARATOR
Intervention: Traditional OC regimen (21/7)
Number of subjects: 115
Study 21324086 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-cycle OC regimen (24/4)
Number of subjects: 115
Study 21324086 — intervention group
Group type: EXPERIMENTAL
Intervention: Both OC regimens
Number of subjects: 115
Study 19475577 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue (FG) as interpositioning layer
Number of subjects: 40
Study 19475577 — intervention group
Group type: COMPARATOR
Intervention: Martius flap (MF) as interpositioning layer
Number of subjects: 40
Study 17261212 — intervention group
Group type: COMPARATOR
Intervention: Lecture-based approach
Number of subjects: 54
Study 17261212 — intervention group
Group type: EXPERIMENTAL
Intervention: Case/problem-based learning discussion
Number of subjects: 54
Study 15564951 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic epidural blood patch with 20 ml autologous blood
Number of subjects: 64
Study 15564951 — intervention group
Group type: COMPARATOR
Intervention: Sham patch
Number of subjects: 64
Study 11481299 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin (AMX) for 10 days
Number of subjects: 45
Study 11481299 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-amoxiclav (AMC) for 10 days
Number of subjects: 45
Study 11481299 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antibiotic therapy)
Number of subjects: 45
Study 9668732 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 3
Study 9668732 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 3
Study 9668732 — intervention group
Group type: COMPARATOR
Intervention: Health education control
Number of subjects: 3
Study 7921858 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol 200 mg
Number of subjects: 45
Study 7921858 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol 100 mg
Number of subjects: 45
Study 7921858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 3292578 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle stretching treatment
Number of subjects: 34
Study 3292578 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment mentioned)
Number of subjects: 34
Study 4980112 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline phosphate complex
Number of subjects: 0
Study 4980112 — intervention group
Group type: EXPERIMENTAL
Intervention: Demethylchlortetracycline hydrochloride
Number of subjects: 0
Study 4980112 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacycline hydrochloride
Number of subjects: 0
Study 4980112 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline hyclate
Number of subjects: 0
Study 31713184 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol 0.25 μg three times daily from transplantation to day 30
Number of subjects: 80
Study 31713184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 29216289 — intervention group
Group type: COMPARATOR
Intervention: Unloaded
Number of subjects: 12
Study 29216289 — intervention group
Group type: EXPERIMENTAL
Intervention: 7% of body mass
Number of subjects: 12
Study 29216289 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% of body mass
Number of subjects: 12
Study 25744852 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive airway pressure at 15 cmH2O plus conventional chest physiotherapy
Number of subjects: 156
Study 25744852 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional chest physiotherapy plus non‐therapeutic positive airway pressure at 4 cmH2O
Number of subjects: 156
Study 25744852 — intervention group
Group type: COMPARATOR
Intervention: Non‐therapeutic positive airway pressure at 4 cmH2O
Number of subjects: 156
Study 24284618 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nucleotides (50 mg/day) for 14 days
Number of subjects: 30
Study 24284618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 21766553 — intervention group
Group type: EXPERIMENTAL
Intervention: L-isoleucine (2 g/L)-added ORS
Number of subjects: 50
Study 21766553 — intervention group
Group type: COMPARATOR
Intervention: ORS without L-isoleucine (control)
Number of subjects: 50
Study 19383056 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus an eight week stroke specific self-management education group program
Number of subjects: 0
Study 19383056 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus a six week generic chronic condition self-management group education program
Number of subjects: 0
Study 19383056 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 16829490 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetition of associative lists
Number of subjects: 0
Study 16829490 — intervention group
Group type: EXPERIMENTAL
Intervention: Separate recognition tests
Number of subjects: 0
Study 16829490 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated lists
Number of subjects: 0
Study 15324105 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive physical activity
Number of subjects: 0
Study 15324105 — intervention group
Group type: COMPARATOR
Intervention: Stable angina pectoris
Number of subjects: 0
Study 11132743 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 130/0.4 (Voluven)
Number of subjects: 59
Study 11132743 — intervention group
Group type: COMPARATOR
Intervention: HES 200/0.5 (pentastarch)
Number of subjects: 59
Study 9296895 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 90
Study 9296895 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 90
Study 9296895 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 90
Study 8380295 — intervention group
Group type: EXPERIMENTAL
Intervention: NWTS-1 treatment regimen
Number of subjects: 0
Study 8380295 — intervention group
Group type: EXPERIMENTAL
Intervention: NWTS-2 treatment regimen
Number of subjects: 0
Study 8380295 — intervention group
Group type: EXPERIMENTAL
Intervention: NWTS-3 treatment regimen
Number of subjects: 0
Study 8380295 — intervention group
Group type: COMPARATOR
Intervention: Patients with specimen weight 550 g or greater
Number of subjects: 0
Study 3946161 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diltiazem (0.25 mg/kg)
Number of subjects: 16
Study 3946161 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diltiazem (0.25 mg/kg) in patients receiving long-term propranolol (120 to 240 mg/day)
Number of subjects: 16
Study 30216377 — intervention group
Group type: EXPERIMENTAL
Intervention: GE S8 2D-SWE
Number of subjects: 100
Study 30216377 — intervention group
Group type: EXPERIMENTAL
Intervention: Samsung RS80A
Number of subjects: 100
Study 30216377 — intervention group
Group type: COMPARATOR
Intervention: Transient Elastography (TE)
Number of subjects: 100
Study 30216377 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 vs. 10 measurements
Number of subjects: 100
Study 30216377 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender comparison (Males vs. Females)
Number of subjects: 100
Study 30216377 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and BMI groups
Number of subjects: 100
Study 27903263 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle Response Testing (MRT)
Number of subjects: 68
Study 27903263 — intervention group
Group type: COMPARATOR
Intervention: Intuition
Number of subjects: 68
Study 27903263 — intervention group
Group type: COMPARATOR
Intervention: Chance
Number of subjects: 68
Study 25133792 — intervention group
Group type: EXPERIMENTAL
Intervention: Music (N=20)
Number of subjects: 62
Study 25133792 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal voice (N=20)
Number of subjects: 62
Study 25133792 — intervention group
Group type: COMPARATOR
Intervention: Control group (N=22)
Number of subjects: 62
Study 23104611 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP), specifically autologous conditioned plasma (ACP), 5.5 mL, 4 intra-articular injections
Number of subjects: 120
Study 23104611 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid (HA), 20 mg/2 mL, 4 intra-articular injections
Number of subjects: 120
Study 23104611 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid (HA), 20 mg/2 mL, 4 intra-articular injections (specifically for grade III gonarthrosis)
Number of subjects: 120
Study 23104611 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP), specifically autologous conditioned plasma (ACP), 5.5 mL, 4 intra-articular injections (specifically for grade III gonarthrosis)
Number of subjects: 120
Study 19815457 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic aerobic endurance training at lower intensity (33% of heart rate reserve) for 10 weeks
Number of subjects: 39
Study 19815457 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic aerobic endurance training at higher intensity (66% of heart rate reserve) for 10 weeks
Number of subjects: 39
Study 19815457 — intervention group
Group type: COMPARATOR
Intervention: Sedentary period between training periods
Number of subjects: 39
Study 18441005 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori 'test and treat' strategy (UBT)
Number of subjects: 432
Study 18441005 — intervention group
Group type: COMPARATOR
Intervention: Prompt endoscopy (OGD)
Number of subjects: 432
Study 16234118 — intervention group
Group type: EXPERIMENTAL
Intervention: LAMK I
Number of subjects: 64
Study 16234118 — intervention group
Group type: COMPARATOR
Intervention: FOE
Number of subjects: 64
Study 12670813 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine (100 mg)
Number of subjects: 65
Study 12670813 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (3 mg)
Number of subjects: 65
Study 12670813 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 65
Study 12670813 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine (100 mg) + Morphine (3 mg)
Number of subjects: 65
Study 10392225 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood sample obtained from normal saline lock with no blood discarded
Number of subjects: 32
Study 10392225 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood sample obtained from normal saline lock after discarding 2 times the dead space (3 mL)
Number of subjects: 32
Study 10392225 — intervention group
Group type: COMPARATOR
Intervention: Venipuncture blood sample
Number of subjects: 32
Study 8913124 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient haemodilution (HD) regimen (packed cell volume of <0.35, 12 weeks)
Number of subjects: 59
Study 8913124 — intervention group
Group type: COMPARATOR
Intervention: Control group (no haemodilution)
Number of subjects: 59
Study 1907535 — intervention group
Group type: COMPARATOR
Intervention: TFT eyedrops
Number of subjects: 50
Study 1907535 — intervention group
Group type: EXPERIMENTAL
Intervention: BVDU eyedrops
Number of subjects: 50
Study 6824608 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron supplementation
Number of subjects: 45
Study 6824608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 31666344 — intervention group
Group type: EXPERIMENTAL
Intervention: R-HDS (high-dose chemotherapy with rituximab and autograft)
Number of subjects: 134
Study 31666344 — intervention group
Group type: COMPARATOR
Intervention: CHOP-R (conventional chemotherapy with rituximab)
Number of subjects: 134
Study 31666344 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete remission
Number of subjects: 134